Reozalimab (Ibi318) (Anti-PD-1 & PD-L1)
Product Specifications
CAS Number
2445259-99-2
Synonyms
LY3434172, Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318
SKU
C00917-1mg
Target
PD-1/PD-L1
Applications
Apoptosis
Additionnal Information
Reozalimab (Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC050017-100 1x 100 µL
Ep-CAM / CD326 (VU-1D9), CF405M conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880270-500 1x 500 µL
Fibronectin (HFN7.1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC881429-500 1x 500 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details